New Zealand medtech innovator Wellumio has successfully closed an oversubscribed pre-Series A funding round, securing NZD $9.75 million. The investment, led by Nuance Connected Capital, is earmarked to advance the company's portable stroke diagnosis technology. This capital injection will accelerate clinical trials, regulatory approvals, and the commercial launch of its flagship device, Axana.
Broad Investor Confidence
The funding round attracted a diverse coalition of supporters, reflecting strong market belief in Wellumio's vision. Alongside lead investor Nuance Connected Capital, participants included Icehouse Ventures, NZ Growth Capital Partners, and Pacific Channel. The final close also welcomed new international backers Bioshore Ventures from Australia and Jumpspace Ventures from the United States.
This international participation underscores growing confidence in the company's mission to transform stroke care globally. Dr. Shieak Tzeng, Co-founder and CEO, noted that the support validates their approach to improving patient outcomes. The round also saw contributions from angel groups like Flying Kiwi and Enterprise Angels, as well as retail investors.
Accelerating Stroke Diagnosis Technology
Wellumio aims to address a critical gap in emergency medicine, where rapid diagnosis is paramount for stroke victims. Many patients miss the "golden hour" for treatment, which significantly impacts their chances of a full recovery. The company's portable, AI-enhanced MRI technology is designed to provide immediate assessment at the point of care.
The core of this innovation is the Axana scanner, a portable 50kg device that operates on battery power. It utilizes Wellumio's proprietary Pulsed Gradient Free Mapping (PGFM) technology, which recently received a U.S. patent. The system uniquely requires no contrast agents, cryogenics, or specialized shielded rooms, making it highly accessible.
The technology's efficacy has been demonstrated in both preclinical studies and initial first-in-human feasibility trials. Results have shown strong agreement with conventional MRI across key stroke biomarkers, supporting continued clinical development. These findings are a crucial step as Wellumio progresses toward regulatory approval and widespread commercialization.
Strategic Use of Capital and Team Expansion
The newly acquired funds will be strategically deployed to fuel the company's next phase of growth. Key priorities include expanding the team, advancing product development, and scaling up clinical evaluations across new sites and geographies. This investment is crucial for bringing the Axana device from development to market readiness.
To support this expansion, Wellumio has bolstered its leadership with key appointments like Harry Marfatia as Head of Finance. Marfatia brings valuable experience from his previous role as APAC Chief Financial Officer at Telix Pharmaceuticals. This move strengthens the company's capability to manage its growth and commercialization efforts effectively.
Investor confidence is high, with partners highlighting the significant global opportunity for improved stroke care. Jeff Reid of Bioshore Ventures praised Axana as being at the forefront of a major shift toward faster diagnosis. Similarly, Adam Caplan of Jumpspace Ventures emphasized the technology's potential to move critical diagnostic information closer to the patient.
With $9.75 million in new funding and robust investor backing, Wellumio is well-positioned to disrupt the landscape of acute stroke diagnosis. The company's innovative Axana device promises to bring rapid, MRI-based imaging directly to the patient's bedside. This advancement could significantly improve treatment timelines and ultimately enhance outcomes for stroke patients worldwide.